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Background: High seroprevalence of parvovirus B19 (B19V) coinfection with Plasmodium falciparum has been
previously reported. However, the impact of B19V-infection on the clinical course of malaria is still elusive. In this
study, we investigated the prevalence and clinical significance of B19V co-infection in Gabonese children with
malaria.
Methods: B19V prevalence was analyzed in serum samples of 197 Gabonese children with P. falciparum malaria
and 85 healthy controls using polymerase chain reaction (PCR), enzyme-linked immunosorbent assay (ELISA), and
direct DNA-sequencing.
Results: B19V was detected in 29/282 (10.28%) of Gabonese children. B19V was observed more frequently in
P. falciparum malaria patients (14.21%) in comparison to healthy individuals (1.17%) (P<0.001). Notably, the
mild-malaria group revealed significantly lower hematocrit levels in B19V/P. falciparum co-infection than in P.
falciparum mono-infection (P<0.05). Genetic analysis revealed a predominance of B19V genotype-1 (71.43%) in the
studied population. However, B19V-genotype 2 was observed significantly more often in children with
severe-malaria than in mild-malaria (P=0.04).
Conclusion: Our findings reveal that B19V-infection is frequent in Gabonese children with P. falciparum malaria and
signifies a possible contribution of B19V on the clinical course of malaria in a genotype-dependent manner. B19V
co-infection should be considered as a additional diagnostic measure in malaria patients with life threatening
anemia.
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Malaria is one of the major causes of morbidity and mor-
tality in tropical and sub-tropical countries and is caused
by the protozoan parasites of the genus Plasmodium while
Plasmodium falciparum (P. falciparum) being the most
virulent species [1].
P. falciparum infected individuals show different cli-
nical phenotypes, which range from asymptomatic infec-
tions to severe forms of malaria. The clinical resolution* Correspondence: bockc@rki.de
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reproduction in any medium, provided the oris influenced by multitude of host and parasite factors
[2]. Recent studies have underlined the importance of
co-infection with human Parvovirus B19 (B19V) in the
etiology and pathogenesis of P. falciparum malaria both
in adults and in children [3-8]. The B19V infection oc-
curs worldwide, with more than 50% are infected with
B19V during early childhood with highest reported cases
among children from tropical countries [7,9].
B19V belongs to the genus Erythrovirus within the fa-
mily of Parvoviridae [10]. Parvoviruses are non-enveloped
DNA viruses that can ably infect mammals [10]. An acute
B19V-infection can cause an impaired erythropoiesis [4].
B19V can have a diverse spectrum of clinical mani-
festations depending on the hematological and thed. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Characteristics of Gabonese children with P.




Age (Month) 44.90 44.23 n.s.













Hemoglobin (g/L) >80 <50 <0.0001
Lactate (mmol/L) 2.4 2.9 <0.05
Parasite × 1000/μL 26.492 407.08 <0.0001
Schizontaemia (n) 0 24 <0.001
n.s. = not significant, values are given as median, values for male/female are
given as numbers.
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can be causative for erythema infectiosum (fifth disease),
hydrops fetalis, and aplastic anemia in individuals with
underlying hemolysis [11]. Other manifestations include
arthritis [12,13], myocarditis [14,15], vasculitic syn-
dromes [16], neurological disorders [17], and hepatic
inflammation [18,19].
B19V-infection has been demonstrated to elevate se-
vere anemia caused by P. falciparum among young chil-
dren in the Republic of Nigeria [7]. The B19V-infection
outbreak in Nigeria reported that 54% of children with
P. falciparum associated severe anemia (hematocrit
level, <20%) showed an evidence of B19V-infection [7].
Similar studies from Ghana, Papua New Guinea, and
Kenya support the finding that B19V can play an im-
portant role in the etiology of severe anemia in children
living in malaria endemic areas [8,20,21]. However,
other studies from Malawi [22] and Kenya [23] observed
little evidence of acute B19V-infection in severe anemia
in children with malaria.
In the present case–control study we utilized 282
healthy and P. falciparum infected Gabonese children
from sub-Sahara Africa. We aim to investigate the preva-
lence of B19V-infection from this malaria endemic area
and further sought to determine the relationship of B19V




282 children were recruited at the Albert Schweitzer
Hospital, Lambaréné, Gabon, and the Centre Hospitalier
de Libreville, Libreville, Gabon. The investigated cohort
is from a matched pair, case–control study, to compare
severe and mild malaria in Gabon. Details of the study
cohort are as described elsewhere [24,25]. Serum sam-
ples of the patients were cryo-freezed and stored as dif-
ferent aliquots at −80°C until use. 197/282 individuals
were infected with P. falciparum with well-characterized
clinical profiles (Table 1). 85/282 children served as
healthy controls and had no evidence and/or clinical
signs of P. falciparum infection during recruitment [26].
The healthy control individuals were chosen of the same
sex, age, and locality and the exclusion criteria were
asymptomatic P. falciparum infection and indications
for concurrent diseases and malnutrition. Among the
197 P. falciparum infected children, individuals were fur-
ther classified in two sub-groups either as severe (n=97)
or mild malaria (n=100) based on clinical signs, symptoms
and parasite load with clinical profiles as shown in Table 1.
Clinical presentation of the severity of P. falciparum in-
fection has been described previously [25,27-29].
Severe malaria was defined as severe anemia (hemo-
globin <50 g/L) and/or hyperparasitemia (> 250,000parasites/ml corresponding to >10% infected erythro-
cytes) and facultative signs of severe malaria, such as
cerebral malaria, convulsions, hypoglycemia, and res-
piratory distress.
Individuals with mild malaria were chosen from pa-
tients of the same sex, age, and locality, and admitted as
soon as the severe cases were enrolled for this study. For
mild malaria, the following criteria were considered:
parasitemia between 1,000/l and 50,000/l on admission,
no schizonts in the periphery, malarial pigment containing
circulating leukocytes <50/μl, hemoglobin >80 g/L, plate-
lets >50/nl, leukocytes <12/nl, and blood glucose >50 mg/
dl (Table 1). Exclusion criteria were signs of severe malaria
and/or other acute infections and prior hospitalization for
any reasons to exclude possible severe malaria in the
history and intake of antimalarial drugs within the prece-
ding weeks.
Polymerase chain reaction (PCR)
Nucleic acid was extracted from patient sera using High
Pure Viral Nucleic Acid Kit (Roche, Grenzach-Wyhlen,
Germany) according to the manufacturer’s instruction.
The detection of B19V-DNA was tested by nested poly-
merase chain reaction (nPCR) as described previously
using primer pairs specific for the VP1/VP2-coding
regions [30]. All samples tested positive for B19V were
reconfirmed with an independent second round of
PCR which amplified the NS1/VP1u-region [31]. PCR
conditions employed were described as in previous
studies [31]. In order to prevent assay contamination,
sample processing (DNA-extraction, template pre-
paration, centrifugation, aliquoting, and master mix
preparation) and PCR-amplification were performed in
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diagnostics and especially for PCR, using standard pre-
cautions. Specificity of PCR products were reconfirmed
by DNA-sequencing. The B19V-DNA sequences were
aligned with published B19V-genome sequences [GenBank
accession number: genotype 1A: M13178, genotype 1B:
DQ357064, genotype 2: AY064476 and AY044266; and
genotype 3: AX003421, AY083234].
Quantitative real-time PCR for B19V-DNA
The B19V-DNA load was determined in the serum by
B19V-specific quantitative real-time PCR (qPCR) using
the GeneAmp 7300 sequence analyser (TaqMan Sequence
Detection System; Applied Biosystems Perkin-Elmer,
Foster City, CA) The primers, probes and program
conditions were used as described previously [30,32].
The specificity and sensitivity of the B19V-qPCR was
determined using the WHO international standards for
B19V-DNA (NIBSC Code 99/800) containing 105 IU/ml
B19V DNA along with integrated B19V-negative control
plasmids. In order to standardize the qPCR, increasing
dilutions of B19V plasmid DNA (6.5 × 104 to 6.5 × 101
B19V IU/ml) were included. The lower sensitivity of the
B19V-qPCR assay was found to be 2 × 102 IU/ml. Sam-
ples were analyzed in duplicates including extraction of
nucleic acids.
DNA sequence analysis
DNA fragments spanning the coding NS1/VP1u region
from nt 2355–2690 (nt. position according to AF162273)
were amplified by nPCR as described previously for all
B19V-DNA positive samples [19,31]. The sequencing
reaction was performed with 5 μl of purified PCR prod-
ucts, 2 μl BigDye Terminator Cycle Sequencing reaction
(Life Technologies Corp., USA), and 15 pmol primer pairs.
The PCR products were sequenced in sense and antisense
direction using primers as described previously [31]. The
primers used for sequencing were sense (n-P5F) 5′-
CGTGAACTGTTAGTTGGGGTTGA-3′ and antisense
(n-P5R) 5′-AATTGCTGATACACAGCTTTAG-3′. The
DNA sequences were analyzed using ABI Prism Genetic
Analyser 3100C (Applied Biosystems, Foster City, USA).
B19V serology evaluation
Anti-B19V-IgM and anti-B19V-IgG (VP1/VP2) were an-
alyzed by enzyme-linked immunosorbent assay (ELISA)
(Parvovirus B19-IgM; Parvovirus B19-IgG, DxSelect™
FocusDiagnostics, Germany) according to the manufac-
turer’s instructions. An Index Value >1.20 measured of
the serum samples in the ELISA assay indicated the
presence of B19V IgG or IgM antibodies. The anti-B19V
IgM ELISA assay has a reported sensitivity of 89% and
specificity of 98% and the anti-B19V IgG ELISA assay a
sensitivity of 96% and specificity of 97%, respectively.B19V-genotype analysis
B19V-sequences were aligned using CLUSTALW (http://
www.ebi.ac.uk/Tools/msa/clustalw2/) and GENEDOC2.5
(http://www.psc.edu/biomed/genedoc). Genetic distances
were calculated using the Kimura two-parameter model in-
corporated into the MEGA5.0 [33]. Phylogenetic trees were
reconstructed by MEGA5.0 using the Neighbour-Joining
method [34]. The robustness of inferred relationships was
assessed with bootstrapping based on 1000 replicate data
sets (bootstrap value < 40 were not shown on the tree).
B19V-sequences available from the GenBank data-
base were used as reference sequences for sequence
alignment [GenBank accession numbers: genotype 1A:
AB030694, AF113323, AF162273, and M13178; genotype
1B: DQ357064, DQ357065, and KF417555; genotype
2: AY064476 and AY044266; and genotype 3: AX003421,
AY083234]. The GenBank accession numbers for the
nucleotide sequences of B19V-samples determined in this
study are from KF309501 to KF309528.
Statistical analysis
Statistical analysis was performed using Statview 4.57
(www.statview.com),JMP Statistical Discovery Software,
version 5.0.1 (www.jmp.com), and Prism5 (version 5.01,
GraphPad Software, San Diego California USA, www.
graphpad.com). A P-value <0.05 was considered to be
statistically significant in all statistical computations. We
computed Fisher’s exact test and the Mann–Whitney
U test and Spearman’s Rho test for our analysis as
accordingly.
Ethical approval
The study was approved by the ethics committee of the
International Foundation for the Albert Schweitzer
Hospital in Lambaréné, Gabon. Informed written con-
sent for participation in the study was obtained from a
parent or guardian of the children.
Results
Prevalence of B19V-DNA and anti-B19V-antibodies
In order to determine the prevalence of B19V-DNA in
sera of the P. falciparum malaria patients we performed
nPCR amplifying the B19V VP1/VP2 and B19V NS1/
VP1u region. Representative nPCR results using B19V-
NS1/VP1u specific primers generating a 336bp B19V-
NS1/VP1 fragment are shown in Figure 1A. NS1/VP1u
amplicons were confirmed by DNA-sequencing (Figure 1B).
Sequencing analysis revealed that sequences differ
between the B19V isolates, thereby excluding cross-
contamination of patient samples representing patient-
specific B19V isolates.
Investigation on the prevalence of B19V in patients
with mild, severe P. falciparum malaria and in controls
showed that B19V-DNA were detectable in 29/282
Figure 1 Qualitative assessment of B19V genomes in Gabonese children with P. falciparum. (A) Representative samples of the qualitative
detection of B19V-DNA in serum of P. falciparum malaria patients using nPCR (lanes 4 to 15). DNA size marker, positive control, and negative
control are shown in lane 1, 2 and 3, respectively. (B) B19V sequences of B19V-positive patients were aligned with reference B19V sequences
using CLUSTALW (http://www.ebi.ac.uk/Tools/msa/clustalw2/), BioEdit (http://www.mbio.ncsu.edu/BioEdit), and GENEDOC_2.5 (http://www.psc.
edu/biomed/genedoc) [GenBank accession No. genotype 1A: M13178, genotype 1B: DQ357064, genotype 2: AY064476 and AY044266; and
genotype 3: AX003421, AY083234]. Sequence homologies are denoted as dots and nucleotide exchanges are shown in letters. The ruler at top of
the sequences is numbered according to the B19V-NS1/VP1 sequences (nt 1 correspond to nt 2355).
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B19V-DNA was significantly higher in patients with
P. falciparum malaria compared to healthy subjects
(14.21% vs. 1.17%, P<0.001; Figure 2A). However, the
proportion of B19V-DNA detection was significantly
higher in the severe and mild malaria patient groups in
comparison to the healthy subjects following the profile:
healthy control < mild malaria < severe malaria (1.17%,
12.37%, and 16%, respectively; Figure 2B) (P<0.01 and
P<0.001; respectively).
Twenty-eight B19V-DNA positive samples of patients
with P. falciparum were examined for anti-B19V-IgM
and anti-B19V-IgG. In total, B19V-IgM and B19V-IgG
antibodies were detected in 20/28 (71.43%) and 19/28
(67.86%) serum samples, respectively. Overlapping anti-
B19V-IgM and anti-B19V-IgG were detected in 11/28
(39.28%) cases, whereas 9/28 (32.14%) patients were anti-
B19V-IgM-positive and anti-B19V-IgG-negative and 8/28
(28.57%) of patients were anti-B19V-IgG-positive and
anti-B19V-IgM-negative.
Additionally simultaneous detection of B19V-DNA
and B19V-IgM antibodies in 71,4% (20/28) of the serumsamples is indicative for an acute or recently acute
B19V-infection rather than a persistence of B19V-DNA.
B19V-loads, parasitemia of P. falciparum, and anemia in
patients with P. falciparum malaria
In order to examine the B19V replication levels of B19V/
P. falciparum co-infections, we examined B19V loads in
the serum of the Gabonese children with malaria. The
B19V loads in sera of B19V/P. falciparum co-infected
patients were 3.08 log10 (range 1.65-4.83) IU/ml. No
significant differences of the B19V loads of sera of mild
malaria patients (median, 2.48 log10 IU/ml [range 1.65-
4.83 IU/ml]) compared to severe malaria patients (median,
3.42 log10 IU/ml [range 1.76-4.11 IU/ml]) were observed,
P>0.05 (Figure 3).
Additionally, the parasitemia of Plasmodium spp. did
not differ significantly in B19V/P. falciparum co-infected
patients compared to mono-infections of P. falciparum
(201.910 ± 184.018 vs. 201.570 ± 276.973 parasites/μL,
respectively, P>0.05; Table 1). However, in the mild
malaria group the parasitemia of P. falciparum patients
co-infected with B19V was marginally higher (41.900 ±
Figure 2 Prevalence of B19V genomes in children with P.
falciparum and healthy controls. (A) Prevalence of B19V-genome
detection in Gabonese patients with P. falciparum malaria and
healthy control group (HC) (odds ratio (OR) = 12.08 (CI95 [1.62-90.28],
two tailed Fisher’s exact test, P<0.001). (B) Distribution of B19V
genomes in Gabonese patients with P. falciparum malaria according
to their clinical presentation of malaria (mild and severe) and in
healthy control group (HC) (OR =10.52 (CI95 [1.34 - 82.6] and
OR=13.6 (CI95 [1.77 - 104.7], respectively, two tailed Fisher’s exact
test, P<0.01).
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infection (23.600 ± 31.277 parasites/μL; P=0.06).
The investigation of hematocrit levels in mild malaria
patients revealed that hematocrit levels were significantly
lower in patients with B19V/P. falciparum co-infectionFigure 3 Serum B19V-DNA loads in co-infected B19V/P.
falciparum/ patients according to clinical presentation of mild
and severe malaria. Serum B19V-DNA loads showed no significant
differences between the mild and severe malaria patient groups
(median, 2.48 log10 IU/ml (range 1.65-4.83 IU/ml) vs 3.42 log10 IU/
ml (range 1.76-4.11 IU/ml), P=ns (Mann–Whitney U test).in comparison to P. falciparum mono-infection (P<0.05;
Figure 4A). However, in severe malaria patients
hematocrit levels were not altered when compared to
B19V/P. falciparum coinfection with P. falciparum
mono-infection (P>0.05; Figure 4B).Distribution of B19V-genotypes in Gabonese children
Currently, three Erythrovirus genotypes (genotype 1, 2
and 3) have been described [35,36] whereas B19V-
genotype 1 seems to be the predominant genotype
worldwide in recent years [37]. In order to examine the
distribution of B19V-genotypes in Gabonese children
with P. falciparum malaria we analysed B19V-positive
samples of the patient cohort using molecular epi-
demiological methods. Sequencing analysis of the sub-
genomic B19V NS1/VP1u region indicated that both
B19V genotypes 1 and 2 were detectable in Gabonese
children. However, B19V-genotype 1 was observed to be
more frequent than genotype 2 (20 of 28 (71.43%) vs. 8
of 28 (28.57%), whilst genotype 3 could not be detected
in the study population.Figure 4 Hematocrit levels of co-infected B19V/P. falciparum
and mono-infected P. falciparum patients. (A) Hematocrit levels
of mono-infected P. falciparum (white box) and B19V/P. falciparum
co-infected (grey box) are denoted. (B) Hematocrit levels of mild
and severe malaria patients are shown. In mild malaria patients, the
hematocrit level co-infected with B19V/P. falciparum patients was
significantly lower in comparison to mono-infected P. falciparum
patients. P<0.05 values are statistically significant (Mann–Whitney
U test).
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the course of P. falciparum malaria (mild and severe), we
examined the distribution of B19V-genotypes in serum of
P. falciparum malaria patients. No significant differences
in the levels of parasitemia, hemoglobin and hematocrit in
the serum of the malaria patients across the different
B19V genotypes were observed (data not shown). Ad-
ditionally, B19V-DNA loads showed no significant dif-
ferences (P>0.05; Figure 5A). However, B19V-genotype 2
was more significantly detected in patients with severe
malaria (7/16) compared to patients with mild malaria
(1/12) (Figure 5B; P<0.05; one tailed Fisher’s exact test).
Recently, our studies demonstrated that B19V-genotype
1 can be classified into at least two B19V sub-genotypes 1,Figure 5 B19V genotype-specific distribution and viral loads in
B19V/P. falciparum coinfected malaria patients. (A) B19V
genotype-specific viral loads was not significantly different
between the malaria patient groups (median, 2.83 log10 IU/ml
(range 1.65-4.83 IU/ml) vs 3.67 log10 IU/ml (range 1.76-4.11 IU/ml),
P=ns (Mann–Whitney U test). (B) Prevalence of B19V genotypes 1
and 2 in mild and severe malaria patient groups. The prevalence of
B19V-genotype 2 was significantly higher in severe malaria than in
mild malaria (OR = 8.56 (CI95 [0.88-83.1], one-tailed Fisher’s exact
test, P<0.05).B19V-1A and B19V-1B [31]. In order to analyze the B19V
sub-genotype in Gabonese children the sub-genomic
NS1/VP1u region of the B19V-positive patient samples
were compared to B19V reference sequences from the
database using phylogenetic analysis. Nineteen B19V-
sequences from the studied Gabonese clustered in a sin-
gle clade of B19V-genotype 1A (67.85%) whereas one
B19V isolate clustered with the other clade of B19V-
subgenotype 1B (Af22m [GenBank: KF309508]). Eight
B19V-sequences clustered with the genotype 2 reference
group (28.57%; Figure 6A).
The genetic distances among the newly detected B19V-
and reference strains were calculated based on the Kimura
two-parameter model using MEGA5.0 software. The re-
sults of the genetic distance analysis of the sub-genomic
B19V NS1/VP1u region of the B19V samples are shown in
Figure 6B. The genetic distances among the B19V-strains
within each B19V-genotype were very low, ranging from
0.009 to 0.063 for B19V-genotype 1 (1A and 1B)(Figure 6B,
No. 1–10) and from 0.000 to 0.056 for B19V-genotype 2
(Figure 6B, No 11–18) while B19V-genotype 3 was not
detected in our study. Further analysis showed that the
genetic distances determined in B19V sub-genotypes 1A
and 1B were also low with highest value of 0.063
(Figure 6B, No 4/genotype 1A and No 10/genotype 1B).
In contrast, the mean distance between different B19V-
genotypes was higher than the mean intra-genotypic
divergence (Figure 6B, >0.129). Overall, the average ge-
netic distance was 0.086 among all B19V-genotypes. The
genotypic identification of B19V-strains was completely
accurate (100%) using both the diagnostic nucleotide and
distance-based/phylogenetic approaches.
Discussion
Malaria due to P. falciparum infection still pose major
health problem in developing countries and in many
sub-Saharan countries such as Gabon. In regions with
high endemicity for P. falciparum infection, the majority
of children with malaria present a mild form of the
disease. A small proportion of individuals infected with
P. falciparum develop severe forms of malaria with a
higher risk of mortality and morbidity [38]. The asso-
ciation of B19V with aplastic crisis in hemolytic diseases
such as sickle cell anemia is well reported, however, their
role in coinfection with P. falciparum malaria is yet con-
troversial. Anemia in malaria is multifactorial and mainly
due to haemolysis and dyserythropoiesis [39]. Recently,
two studies in children of Papua New Guinea showed
that certain common infections, and especially B19V-
infection can play a critical role in the etiology of severe
anemia besides other factors, such as malnutrition and
iron deficiency, in a highly endemic area for malaria
[21,40]. This finding was further supported by yet an-
other study showing that high B19V IgM levels were
Figure 6 (See legend on next page.)
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Figure 6 Phylogenetic analysis of the B19V-NS1/VP1u region. (A) The phylogenetic tree has been inferred from the B19V-NS1/VP1u region
(nt 2355 to nt 2690) of 39 B19V-samples. Topology was constructed by MEGA 5.0 software using the Neighbor-joining method with bootstrap
values (in percent) indicating numbers from 1,000 replicates tested (values <40 were not shown). Major lineages of B19V are shown as branches.
The two major B19V-subtypes 1A and 1B are shown [31]. Scale bar at bottom indicates the number of nucleotide substitutions per site. Patient
codes and the corresponding GenBank accession number are denoted (e.g., Af31m(KF309528)). Reference B19V-sequences were GenBank
accession No. AB030694, AF113323, M13178 and AF162273 for B19V-genotype 1A, DQ357064, DQ357065, and KF417555 for B19V-genotype 1B,
AY064476 and AY044266 for B19V-genotype 2, and AX003421 and AY083234 for B19V-genotype 3. (B) Genetic distance calculation (Kimura
two-parameter model) of B19V-strains. Numbers at the left denote patient-specific B19V-strains and B19V-reference strains [Genbank numbers are
denoted]: [1] M131178; [2] AB030694; [3] Af21s (KF309511); [4] Af13s (KF309513); [5] Af33s (KF309514); [6] Af34m; [7] Af41s (KF309516); [8] Af22m
(KF309508); [9] DQ357064; [10] DQ357065; [11] AY064476; [12] AY044266; [13] Af2m (KF309519); [14] Af37s (KF3095021); [15] Af38s (KF3095020);
[16] Af35s (KF3095027); [17] Af39s (KF3095022); [18] Af40s (KF3095026); [19] AY083234; [20] AX003421. B19V-reference strains are genotype 1: [1],
[2], genotype 2: [11], [12], and genotype 3: [19], [20]. Boxes represent data of the genetic distance calculation of the same genotype
and sub-genotype.
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children [20]. B19V-infection can result in severe anemia
since B19V selectively inhibits and lysates actively repli-
cating erythroid progenitor cells [11,41]. Notably, target
cells of B19V are erythroid cells and erythroid precursors
which are shared by P. falciparum probably resulting in
case of co-infection in more severe anemia [7,21,42-44].
A previous study has shown a high prevalence of
B19V and P. falciparum co-infection in Nigeria [7]. In
contrast, other studies from Malawi [22], Ghana [8], and
Kenya [20,45] found little evidence of acute B19V infec-
tion in children (either anemic or control).
In accordance to the study of Nigeria, we could dem-
onstrate that B19V genomes were detectable in 10.28%
of young Gabonese individuals while the frequency of
B19V was significantly higher in P. falciparum malaria
patients than in healthy children (P<0.001, Figure 2).
Children with severe P. falciparum malaria showed the
highest rate of B19V infection (16.0%) when compared
to mild malaria (12.37%). These findings suggest that
B19V may probably play a role in the pathogenesis of P.
falciparum malaria following a B19V prevalence profile
of healthy control < mild malaria < severe malaria. In ac-
cordance with our findings on increased B19V detection
in P. falciparum malaria patients, a previous report sug-
gested that depression of cell-mediated immunity in P.
falciparum infection might favour co-infection with
opportunistic pathogens including B19V [46].
With regard to clinical outcome of P. falciparum ma-
laria previous studies have shown a failure of recovery
of hemoglobin after effective anti-malarial treatment
and delayed recovery of P. falciparum malaria after
subsidence of B19V infection [3,42]. Furthermore, the
association of B19V infection with hemoglobin levels
may be related to individual variability. Studies have
shown previously that a significant decrease in hemo-
globin levels can occur in patients with P. falciparum
malaria [3,47]. These findings corroborate well with our
observation of significantly lower hematocrit levels inB19V/P. falciparum co-infected patients in comparison
to P. falciparum mono-infection (P<0.05; Figure 4).
Evaluation of B19V loads, which showed mainly acute
B19V-infection due to positive B19V-IgM results (67,86%),
and parasitemia showed no significant differences bet-
ween mild and severe malaria groups in the studied
population possibly postulate that there is no direct or
indirect interaction of B19V and P. falciparum with
regards to viral replication. However, a slightly but not
significant increase in parasitemia could be observed in
mild malaria co-infected with B19V in comparison to
mono-infection of P. falciparum (P>0.05; Table 1).
Different genotypes of viruses, such as human immuno-
deficiency virus (HIV) and hepatitis B and C viruses, show
different susceptibility to disease progression or response
to antiviral treatment. We therefore analysed the distribu-
tion of B19V-genotypes in the studied P. falciparum
patients. Only Erythrovirus (B19V)-genotypes 1 and 2
were observed in the studied population, however geno-
type 3 cannot be observed in our study population. B19V-
genotype 1, and especially B19V-genotype 1A, was the
most prevalent genotype in Gabonese children. This is in
accordance with previous studies showing a predomi-
nance of B19V-genotype 1 worldwide [31,35,48,49]. Inte-
restingly, B19V genotype 2 was found in 28.6% of the
young Gabonese children. These findings were unex-
pected as recent reports indicated that B19V-genotype 1
and 2 follow an age-dependent distribution while B19V
genotype 1 is detectable mainly in younger people
(<45 years) and genotype 2 can mostly be observed in
patients older than 60 years [15,50]. However, a geogra-
phical distribution of B19V genotype 2 could not be com-
pletely excluded as it has been shown for genotype 3 [51].
We did not observe any significant differences in
parasitemia, hemoglobin and hematocrit levels of P.
falciparum malaria patients across the different B19V
genotypes 1 and 2. However, genotype 2 was detected sig-
nificantly more often in children with severe-malaria com-
pared to children with mild-malaria (P<0.05). The
Toan et al. BMC Infectious Diseases 2013, 13:375 Page 9 of 10
http://www.biomedcentral.com/1471-2334/13/375detected association of B19V-genotype 2 with severe ma-
laria needs further analysis, although, one can postulate
that variability in the host immune response to distinct
B19V-genotypes may correspond with the severity of
anemia in B19V/P. falciparum patients.
Conclusions
Overall to our knowledge this is the first study which sup-
ports the hypothesis that an acute B19V infection can
modulate the clinical course of P. falciparum malaria in
Gabonese children. Additionally, our results point towards
increased B19V co-infection among young children with
P. falciparum malaria. Two of the three Erythrovirus
genotypes are detected in these populations while geno-
type 2 remained more frequent in children with severe
malaria. The hematocrit levels of B19V/P. falciparum co-
infected mild-malaria patients were significantly decreased
as a consequence of co-infection. These findings indicate
that the clinical outcome of P. falciparum malaria in Ga-
bonese children is influenced by B19V co-infection and
should be considered as a diagnostic measure in patients
with worsening anemia and persistent fever in spite of
effective anti-malarial therapy. However the precise mo-
lecular mechanisms involved in B19V co-infection in the
context of pathogenesis of P. falciparum malaria yet needs
to be understood and warrants further analysis.
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